AU3270301A - Combined pde3 and pde4 inhibitor therapy for the treatment of obesity - Google Patents
Combined pde3 and pde4 inhibitor therapy for the treatment of obesityInfo
- Publication number
- AU3270301A AU3270301A AU32703/01A AU3270301A AU3270301A AU 3270301 A AU3270301 A AU 3270301A AU 32703/01 A AU32703/01 A AU 32703/01A AU 3270301 A AU3270301 A AU 3270301A AU 3270301 A AU3270301 A AU 3270301A
- Authority
- AU
- Australia
- Prior art keywords
- obesity
- treatment
- pde4 inhibitor
- inhibitor therapy
- pde3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16541899P | 1999-11-13 | 1999-11-13 | |
US60165418 | 1999-11-13 | ||
PCT/US2000/042137 WO2001035979A2 (en) | 1999-11-13 | 2000-11-13 | Combined pde3 and pde4 inhibitor therapy for the treatment of obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3270301A true AU3270301A (en) | 2001-05-30 |
Family
ID=22598815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU32703/01A Abandoned AU3270301A (en) | 1999-11-13 | 2000-11-13 | Combined pde3 and pde4 inhibitor therapy for the treatment of obesity |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3270301A (en) |
WO (1) | WO2001035979A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002051502A1 (en) * | 2000-12-22 | 2002-07-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combined inhibition of phosphodiesterase-4 (pde-4) and phosphodiesterase-3 (pde-3) as a therapy for th1-mediated autoimmune diseases |
JP2004536614A (en) * | 2001-08-01 | 2004-12-09 | ユニバーシティ オブ ユタ | PDE3 cyclic nucleotide phosphodiesterase isoform-selective inhibitors and activators |
FR2849594B1 (en) * | 2003-01-03 | 2006-10-27 | Oreal | USE OF ZARDAVERINE AS SLIMMING |
US7776893B2 (en) | 2003-09-05 | 2010-08-17 | Nycomed Gmbh | Use of PDE4 inhibitors for the treatment of diabetes mellitus |
WO2006094933A1 (en) | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
KR20090047546A (en) | 2006-09-07 | 2009-05-12 | 니코메드 게엠베하 | Combination treatment for diabetes mellitus |
JPWO2009154230A1 (en) * | 2008-06-17 | 2011-12-01 | 持田製薬株式会社 | Non-alcoholic steatohepatitis prevention / improvement / treatment drug |
WO2011162320A1 (en) * | 2010-06-23 | 2011-12-29 | 国立大学法人九州大学 | Combination of egcg or methylated egcg and a pde inhibitor |
US20150359798A1 (en) * | 2011-09-06 | 2015-12-17 | Jansfat Biotechnology Co., Ltd. | Piperazinyl derivative reduces high-fat diet-induced accumulation of fat in the livers, therapeutically |
CA3026083C (en) * | 2016-06-03 | 2024-04-02 | The Trustees Of Columbia University In The City Of New York | Methods of treating prader-willi syndrome |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001516765A (en) * | 1997-09-12 | 2001-10-02 | ヴォルフ ゲオルグ フォースマン | Compositions for the treatment of diabetes mellitus and obesity |
-
2000
- 2000-11-13 AU AU32703/01A patent/AU3270301A/en not_active Abandoned
- 2000-11-13 WO PCT/US2000/042137 patent/WO2001035979A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2001035979A3 (en) | 2002-01-03 |
WO2001035979A2 (en) | 2001-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL362477A1 (en) | Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases | |
AU2003200722A1 (en) | Compositions and methods for the treatment of tumor | |
AU2003200740A1 (en) | Compositions and methods for the treatment of tumor | |
AU2003200731A1 (en) | Compositions and methods for the treatment of tumor | |
AU2495200A (en) | Compositions and methods for the treatment of tumor | |
AU2072201A (en) | Agents and methods for the treatment of proliferative diseases | |
AU2002259130A1 (en) | Agents for treatment of hcv and methods of use | |
AU2001269314A1 (en) | Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds | |
AU2001265253A1 (en) | Treatment of hiv using hyperthermia | |
AU6435398A (en) | Prevention and treatment of hepatocellular cancer | |
AU2002237667A1 (en) | Methods for the treatment and prevention of urinary stone disease | |
AU2001228703A1 (en) | Use of cox-2 inhibitors for the treatment of constipation | |
AU5908300A (en) | Prevention and treatment of amyloid-associated disorders | |
AU3270301A (en) | Combined pde3 and pde4 inhibitor therapy for the treatment of obesity | |
AU3960801A (en) | Gear and procedure of achievement | |
AU2001255521A1 (en) | Biphasic reaction vessel and methods of use | |
AU2002349268A1 (en) | Medicine for preventing and treating bromidrosis | |
AU7601400A (en) | Treatment and prevention of hepatic disorders | |
AU7105498A (en) | Combination therapy for the prevention and treatment of osteoporosis | |
AU2432001A (en) | Treatment of mental conditions including depression | |
AU3760900A (en) | Treatment of menstrual function | |
AU2566201A (en) | Compounds and methods for the treatment of pain | |
AU5552400A (en) | Treatment of cancer | |
AUPQ367699A0 (en) | Treatment of cancer | |
AU2002222125A1 (en) | Prevention and treatment of tachyphylactic response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |